NCT00388999View on ClinicalTrials.gov

Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

May 31, 2009

Conditions
Multiple Myeloma
Interventions
DRUG

Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)

Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

DRUG

Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)

Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

DRUG

Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)

Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

Trial Locations (1)

72205

University of Arkansas for Medical Sciences, Little Rock

Sponsors
All Listed Sponsors
lead

Enzon Pharmaceuticals, Inc.

INDUSTRY